A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs EYP 001 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors ENYO Pharma
- 13 Jun 2017 According to an ENYO Pharma media release, data from the study has been presented at the international liver conference.
- 13 Jun 2017 Results published in an ENYO Pharma media release.
- 06 Apr 2017 Status changed from recruiting to completed.